214 related articles for article (PubMed ID: 36228734)
1. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
2. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
4. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
[TBL] [Abstract][Full Text] [Related]
5. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38353152
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
11. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
13. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
[TBL] [Abstract][Full Text] [Related]
14. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
18. A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.
Simadibrata DM; Lesmana E; Pratama MIA; Sugiharta AJ; Winarizal AS; Lee YY; Syam AF
JGH Open; 2024 Mar; 8(3):e13053. PubMed ID: 38523708
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
[TBL] [Abstract][Full Text] [Related]
20. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Raghunath AS; Green JR; Edwards SJ
Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
